Phase I/II trial of a low-emetic combination of S-1 plus docetaxel (DTX) for advanced non-small cell lung cancer (NSCLC).Kenichiro Komiyama, Yuka Uchida, Takashi Kasai et al.|Journal of Clinical Oncology|2011Cited by 0
Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)Yosuke Kawashima, Hiroshi Kagamu, Ou Yamaguchi et al.|Annals of Oncology|2019Cited by 0